2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
J

2020 ASCO Update on FDA Approved Selpercatinib in RET-Driven Thyroid Cancers: What Are the Benefits and AE? Is There Cross-Resistance with Selpercatinib and Pralsetinib?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Jochen Lorch
By 2020 ASCO Virtual Direct™ Highlights FEATURING Jochen Lorch
16 views
September 17, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Head&Neck
13:07
2020 ASCO Virtual Direct™ Highlights

ASCO 2020 H&N Cancers Update: Post-Operative CRT in High-Risk Pa…

Feat. J. Lorch
10:13
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Thyroid Cancers: Can the Addition of Pembro Incr…

Feat. J. Lorch
06:34
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on FDA Approved Selpercatinib in RET-Driven Thyroid…

Feat. J. Lorch